Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With Psoriasis

Completed

Conditions studied: Psoriasis

In brief

The study was conducted to describe the demographics, disease characteristics, disease severity, comorbidities and patient reported outcomes at baseline and follow-up periods among adult patients diagnosed with PsO in CorEvitas' PsO Registry under routine medical care initiating secukinumab (SEC).

Key facts

Study ID

NCT05513014

Run by

Novartis Pharmaceuticals

People needed

1518

Starts

2021-03-21

Expected to finish

2021-08-31

Last updated by the study team

2022-11-08

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The patient must:
• Have been diagnosed with PsO by a dermatologist.
• Be at least 18 years of age.
• Be willing and able to provide written informed consent for participation in the registry.
• Have started on or switched to an eligible systemic PsO treatment at enrollment1 or within the previous 12 months of the date of enrollment.

You may not qualify if…

• Patient is participating in or planning to participate in an interventional clinical trial with a nonmarketed or marketed investigational drug (i.e. phase I-IV drug trial).

Where it is running

• Novartis Pharmaceuticals — East Hanover, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.